The observation that treatment with NOA2 led to an accumulation of hCD45+ and hCD33+ immune cells in Ewing tumors in the PBL-NSG mouse study above led us to perform a second treatment study in CD34+ HSC-reconstituted NSG-SGM3 mice which show enhanced engraftment of human myeloid cells [27,28]. The gene discussed is CD34; the disease is Ewing sarcoma.